

	Log-OR from MTC (95% CrI)	Log-OR from head-to-head (95% CI)	OR from MTC (95% CrI)	OR from head-to-head (95% CI)
<b><i>HBeAg-positive patients - HBV DNA (random effects model)</i></b>				
placebo versus lamivudine	-2.275 (-3.706, -0.987)	-1.108 (-2.086, -0.131)	0.129 (0.025, 0.373)	0.33 (0.12, 0.88)‡
adefovir versus lamivudine	0.429 (-0.597, 1.743)		1.861 (0.551, 5.715)	
telbivudine versus lamivudine	1.025 (0.243, 2.017)	0.826 (0.556, 1.095)	3.091 (1.275, 7.517)	2.32 (1.79, 3.01)‡
entecavir versus lamivudine	1.508 (0.801, 2.451)	1.327 (1.088, 1.566)	4.941 (2.228, 11.6)	3.73 (2.94, 4.73)‡
tenofovir versus lamivudine	3.48 (1.861, 5.422)		52.78 (6.427, 226.4)	
Telbivudine+LAM versus lamivudine	0.625 (-0.836, 2.229)	0.702 (-0.426, 1.831)	2.576 (0.434, 9.292)	2.02 (0.65, 6.24)
ADV+LAM versus lamivudine	-0.086 (-1.467, 1.295)	-0.09 (-0.847, 0.668)	1.182 (0.231, 3.651)	0.91 (0.43, 1.95)
adefovir versus placebo	2.704 (1.446, 4.387)	4.408 (1.607, 7.209)	20.98 (4.247, 80.38)	
telbivudine versus placebo	3.3 (1.921, 4.949)		38.7 (6.829, 141.1)	
entecavir versus placebo	3.783 (2.416, 5.438)		62.06 (11.2, 230)	
tenofovir versus placebo	5.755 (3.975, 7.971)		617.3 (53.26, 2897)	
Telbivudine+LAM versus placebo	2.899 (0.987, 5.006)		34.41 (2.682, 149.3)	
ADV+LAM versus placebo	2.189 (0.298, 4.171)		15.42 (1.346, 64.8)	
telbivudine versus adefovir	0.596 (-0.56, 1.654)	0.811 (-0.037, 1.659)	2.109 (0.571, 5.228)	2.25 (0.96, 5.25)
entecavir versus adefovir	1.079 (-0.117, 2.182)	1.773 (0.651, 2.894)	3.457 (0.89, 8.865)	5.89 (1.92, 18.07)‡
tenofovir versus adefovir	3.051 (1.686, 4.43)	3.01 (2.296, 3.725)	26.93 (5.399, 83.92)	20.3 (9.93, 41.48)‡
Telbivudine+LAM versus adefovir	0.196 (-1.729, 1.93)		1.872 (0.177, 6.89)	
ADV+LAM versus adefovir	-0.515 (-2.466, 1.117)		0.892 (0.085, 3.056)	
entecavir versus telbivudine	0.483 (-0.612, 1.593)		1.885 (0.542, 4.92)	
tenofovir versus telbivudine	2.455 (0.767, 4.279)		18.52 (2.153, 72.17)	
Telbivudine+LAM versus telbivudine	-0.4 (-2.076, 1.219)	-0.493 (-1.359, 0.373)	0.958 (0.126, 3.383)	0.61 (0.26, 1.45)
ADV+LAM versus telbivudine	-1.111 (-2.853, 0.431)		0.463 (0.058, 1.538)	
tenofovir versus entecavir	1.972 (0.261, 3.793)		11.42 (1.299, 44.41)	
Telbivudine+LAM versus entecavir	-0.883 (-2.625, 0.78)		0.604 (0.072, 2.182)	
ADV+LAM versus entecavir	-1.593 (-3.314, -0.08)		0.281 (0.036, 0.924)	

	Log-OR from MTC (95% CrI)	Log-OR from head-to-head (95% CI)	OR from MTC (95% CrI)	OR from head-to-head (95% CI)
Telbivudine+LAM versus tenofovir	-2.856 (-5.198, -0.664)		0.121 (0.006, 0.515)	
ADV+LAM versus tenofovir	-3.566 (-5.968, -1.496)		0.057 (0.003, 0.224)	
ADV+LAM versus Telbivudine+LAM	-0.71 (-2.842, 1.259)		0.873 (0.058, 3.523)	
<b><i>HBeAg-positive patients - HBeAg seroconversion (fixed effects model)</i></b>				
placebo versus lamivudine	-0.973 (-1.547, -0.43)	-0.941 (-1.56, - 0.321)	0.393 (0.213, 0.65)	0.38 (0.21, 0.71)‡
adefovir versus lamivudine	-0.109 (-0.761, 0.532)		0.946 (0.467, 1.703)	
telbivudine versus lamivudine	0.112 (-0.19, 0.412)	0.057 (-0.26, 0.375)	1.132 (0.827, 1.51)	1.10 (0.81, 1.50)
entecavir versus lamivudine	0.015 (-0.277, 0.308)	0.045 (-0.253, 0.344)	1.027 (0.758, 1.361)	1.04 (0.78, 1.41)
tenofovir versus lamivudine	0.123 (-0.82, 1.093)		1.275 (0.441, 2.984)	
Telbivudine+LAM versus lamivudine	-0.777 (-1.897, 0.254)	-0.469 (-1.852, 0.914)	0.532 (0.15, 1.289)	0.63 (0.16, 2.49)
ADV+LAM versus lamivudine	0.205 (-0.624, 1.034)	0.205 (-0.624, 1.034)	1.344 (0.536, 2.814)	1.23 (0.54, 2.81)
adefovir versus placebo	0.864 (0.226, 1.526)	0.805 (-0.013, 1.623)	2.509 (1.253, 4.6)	2.24 (0.99, 5.07)
telbivudine versus placebo	1.085 (0.484, 1.709)		3.109 (1.622, 5.525)	
entecavir versus placebo	0.989 (0.383, 1.612)		2.824 (1.466, 5.011)	
tenofovir versus placebo	1.096 (0.155, 2.078)		3.38 (1.168, 7.989)	
Telbivudine+LAM versus placebo	0.196 (-1.04, 1.363)		1.46 (0.354, 3.906)	
ADV+LAM versus placebo	1.178 (0.186, 2.18)		3.701 (1.204, 8.85)	
telbivudine versus adefovir	0.221 (-0.427, 0.884)	0.506 (-0.49, 1.501)	1.319 (0.653, 2.421)	1.66 (0.61, 4.49)
entecavir versus adefovir	0.125 (-0.545, 0.805)	-0.45 (-1.718, 0.818)	1.202 (0.58, 2.237)	0.64 (0.18, 2.27)
tenofovir versus adefovir	0.232 (-0.449, 0.962)	0.221 (-0.475, 0.917)	1.347 (0.639, 2.617)	1.25 (0.62, 2.50)
Telbivudine+LAM versus adefovir	-0.668 (-1.924, 0.533)		0.621 (0.146, 1.703)	
ADV+LAM versus adefovir	0.314 (-0.735, 1.371)		1.581 (0.479, 3.939)	
entecavir versus telbivudine	-0.096 (-0.51, 0.321)		0.929 (0.601, 1.379)	
tenofovir versus telbivudine	0.011 (-0.95, 0.989)		1.142 (0.387, 2.687)	
Telbivudine+LAM versus telbivudine	-0.889 (-1.991, 0.122)	-0.934 (-2.004, 0.135)	0.473 (0.137, 1.13)	0.39 (0.13, 1.14)
ADV+LAM versus telbivudine	0.093 (-0.789, 0.976)		1.216 (0.454, 2.653)	

	Log-OR from MTC (95% CrI)	Log-OR from head-to-head (95% CI)	OR from MTC (95% CrI)	OR from head-to-head (95% CI)
tenofovir versus entecavir	0.108 (-0.861, 1.096)		1.262 (0.423, 2.991)	
Telbivudine+LAM versus entecavir	-0.792 (-1.953, 0.274)		0.529 (0.142, 1.315)	
ADV+LAM versus entecavir	0.19 (-0.696, 1.07)		1.338 (0.499, 2.915)	
Telbivudine+LAM versus tenofovir	-0.9 (-2.349, 0.483)		0.525 (0.095, 1.622)	
ADV+LAM versus tenofovir	0.082 (-1.188, 1.343)		1.335 (0.305, 3.83)	
ADV+LAM versus Telbivudine+LAM	0.982 (-0.353, 2.371)		3.416 (0.703, 10.71)	
<b><i>HBeAg-positive and -negative patients combined - HBV DNA (random effects model)</i></b>				
placebo versus lamivudine	-2.76 (-4.154, -1.576)	-1.108 (-2.086, -0.131)	0.077 (0.016, 0.207)	0.34 (0.16, 0.71)‡
adefovir versus lamivudine	0.657 (-0.296, 1.861)		2.274 (0.744, 6.431)	
telbivudine versus lamivudine	1.085 (0.464, 1.873)	0.886 (0.649, 1.123)	3.161 (1.59, 6.505)	1.9 (1.51, 2.39)‡
entecavir versus lamivudine	1.482 (0.902, 2.238)	1.315 (1.105, 1.525)	4.666 (2.464, 9.374)	2.83 (2.29, 3.49)‡
tenofovir versus lamivudine	3.196 (1.928, 4.757)		33.29 (6.876, 116.4)	
Telbivudine+LAM versus lamivudine	0.652 (-0.775, 2.202)	0.702 (-0.426, 1.831)	2.588 (0.461, 9.044)	2.02 (0.65, 6.24)
ADV+LAM versus lamivudine	-0.077 (-1.405, 1.265)	-0.09 (-0.847, 0.668)	1.167 (0.246, 3.544)	0.91 (0.43, 1.95)
adefovir versus placebo	3.417 (2.295, 4.992)	4.603 (2.621, 6.585)	41.46 (9.922, 147.2)	
telbivudine versus placebo	3.845 (2.596, 5.411)		63.45 (13.41, 223.8)	
entecavir versus placebo	4.242 (3.006, 5.786)		93.75 (20.22, 325.7)	
tenofovir versus placebo	5.956 (4.562, 7.838)		617 (95.75, 2535)	
Telbivudine+LAM versus placebo	3.412 (1.61, 5.508)		55.15 (5.001, 246.6)	
ADV+LAM versus placebo	2.683 (0.93, 4.635)		25.56 (2.534, 103)	
telbivudine versus adefovir	0.428 (-0.701, 1.414)	0.811 (-0.037, 1.659)	1.753 (0.496, 4.114)	2.25 (0.96, 5.25)
entecavir versus adefovir	0.825 (-0.31, 1.844)	1.773 (0.651, 2.894)	2.62 (0.733, 6.32)	5.89 (1.92, 18.07)‡
tenofovir versus adefovir	2.539 (1.634, 3.475)	2.516 (1.593, 3.44)	14.09 (5.126, 32.3)	2.57 (1.72, 3.82)‡
Telbivudine+LAM versus adefovir	-0.005 (-1.851, 1.696)		1.467 (0.157, 5.453)	
ADV+LAM versus adefovir	-0.734 (-2.594, 0.847)		0.684 (0.075, 2.333)	
entecavir versus telbivudine	0.397 (-0.529, 1.32)		1.65 (0.59, 3.743)	

	<b>Log-OR from MTC (95% CrI)</b>	<b>Log-OR from head-to-head (95% CI)</b>	<b>OR from MTC (95% CrI)</b>	<b>OR from head-to-head (95% CI)</b>
tenofovir versus telbivudine	2.111 (0.805, 3.585)		10.9 (2.236, 36.04)	
Telbivudine+LAM versus telbivudine	-0.433 (-1.984, 1.102)	-0.493 (-1.359, 0.373)	0.883 (0.138, 3.01)	0.61 (0.26, 1.45)
ADV+LAM versus telbivudine	-1.163 (-2.756, 0.269)		0.418 (0.064, 1.308)	
tenofovir versus entecavir	1.714 (0.375, 3.202)		7.406 (1.455, 24.58)	
Telbivudine+LAM versus entecavir	-0.83 (-2.466, 0.767)		0.607 (0.085, 2.152)	
ADV+LAM versus entecavir	-1.559 (-3.146, -0.137)		0.279 (0.043, 0.872)	
Telbivudine+LAM versus tenofovir	-2.544 (-4.63, - 0.654)		0.13 (0.01, 0.52)	
ADV+LAM versus tenofovir	-3.273 (-5.38, - 1.471)		0.06 (0.005, 0.23)	
ADV+LAM versus Telbivudine+LAM	-0.73 (-2.782, 1.227)		0.816 (0.062, 3.412)	